Ovid Therapeutics
OVID
35 hedge funds and large institutions have $18.7M invested in Ovid Therapeutics in 2019 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 11 increasing their positions, 15 reducing their positions, and 16 closing their positions.
5.6% less ownership
Funds ownership: 31.77% → 26.16% (-5.6%)
14% less capital invested
Capital invested by funds: $21.7M → $18.7M (-$3.01M)
27% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 15
30% less funds holding
Funds holding: 50 → 35 (-15)
81% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$792K |
| 2 |
Millennium Management
New York
|
+$621K |
| 3 |
BI
BVF Inc
San Francisco,
California
|
+$518K |
| 4 |
Wells Fargo
San Francisco,
California
|
+$230K |
| 5 |
Renaissance Technologies
New York
|
+$194K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$3.15M |
| 2 |
BlackRock
New York
|
-$939K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$453K |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
-$398K |
| 5 |
State Street
Boston,
Massachusetts
|
-$333K |
OVID Hedge Fund Activity: Q2 2019 in Review
35 of the 4,605 institutional investors tracked by Wall St. Rank reported a position in Ovid Therapeutics (OVID) for Q2 2019, worth a combined $18.7M — down 14% from $21.7M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of OVID and 3 opened new positions — a net loss of 13 holders — while 15 trimmed existing stakes and 11 added.
The largest buyer was Vanguard Group, adding an estimated $792K. The largest seller was Armistice Capital, exiting entirely with an estimated $3.15M sold.
- 35 institutional investors held Ovid Therapeutics (OVID) as of Q2 2019, down from 50 in Q1 2019.
- Funds reported $18.7M of Ovid Therapeutics stock for Q2 2019, down 14% quarter-over-quarter.
- 3 funds opened new Ovid Therapeutics positions in Q2 2019 and 16 closed out, a net change of -13 holders.
- The largest Ovid Therapeutics buyer in Q2 2019 was Vanguard Group, an estimated $792K added.
- The largest Ovid Therapeutics seller in Q2 2019 was Armistice Capital, an estimated $3.15M sold.
Based on aggregated 13F filings for Q2 2019.